Viatris — Third Quarter 2026 Earnings Summary

Viatris reported third-quarter 2026 total revenues of $3.75 billion, with a U.S. GAAP net loss of $325 million and adjusted EBITDA of $1.20 billion. The company received regulatory approvals for RYZUMVI in the U.S. for presbyopia and WAKIX in Japan, while announcing a definitive agreement to acquire Pacira BioSciences for $1.65 billion. Viatris raised its 2026 financial guidance midpoints for total revenues, adjusted EBITDA, adjusted EPS, and free cash flow, reflecting strong operational momentum and cost discipline. Additionally, the company returned approximately $717 million to shareholders year-to-date through capital returns and share repurchases.